Salix Pharmaceuticals (SLXP) & Its Peers Critical Analysis

Salix Pharmaceuticals (NASDAQ: SLXP) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its peers? We will compare Salix Pharmaceuticals to similar businesses based on the strength of its dividends, earnings, profitability, valuation, institutional ownership, analyst recommendations and risk.

Volatility & Risk

Salix Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Salix Pharmaceuticals’ peers have a beta of 1.12, meaning that their average stock price is 12% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Salix Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Salix Pharmaceuticals 0 0 0 0 N/A
Salix Pharmaceuticals Competitors 69 335 989 29 2.69

As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 22.98%. Given Salix Pharmaceuticals’ peers higher probable upside, analysts clearly believe Salix Pharmaceuticals has less favorable growth aspects than its peers.

Profitability

This table compares Salix Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Salix Pharmaceuticals -2,134.34% -305.24% -25.83%
Salix Pharmaceuticals Competitors -581.63% -63.32% -26.72%

Valuation & Earnings

This table compares Salix Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Salix Pharmaceuticals N/A N/A -26.55
Salix Pharmaceuticals Competitors $3.02 billion $642.98 million -87.01

Salix Pharmaceuticals’ peers have higher revenue and earnings than Salix Pharmaceuticals. Salix Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

64.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 10.7% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Salix Pharmaceuticals peers beat Salix Pharmaceuticals on 7 of the 8 factors compared.

Salix Pharmaceuticals Company Profile

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Receive News & Ratings for Salix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply